Marketing authorisation variations for medicinal products

This procedure concerns proposed changes to the rules governing marketing authorisations for medicines. It aims to update and clarify the conditions under which medicines can be approved and sold within the EU.

The changes will affect pharmaceutical companies seeking or holding authorisations, and potentially impact the availability and regulation of medicines for both human and animal use.